Charles Schwab’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
Other funds holding KYMR
BBA
Charles Schwab's KYMR Position: Q3 2026 in Review
Charles Schwab increased its Kymera Therapeutics (KYMR) stake by 67% in Q3 2026, buying an estimated $40.9M and bringing the position to 886,951 shares worth $99.2M. The position accounts for 0.01% of the portfolio, ranked #805.
Charles Schwab first reported a position in KYMR in Q4 2020 and has held it in 24 quarters since. 292 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.
- Charles Schwab held 886,951 shares of Kymera Therapeutics worth $99.2M as of Q3 2026.
- Charles Schwab bought 357,222 Kymera Therapeutics shares in Q3 2026, an estimated $40.9M.
- Kymera Therapeutics made up 0.01% of Charles Schwab's portfolio in Q3 2026, its #805 holding.
- Charles Schwab first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 24 quarters since.
- 292 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.
Based on Charles Schwab's 13F filing for Q3 2026, filed 16 Nov 2026.